DataMeds AI, Inc.
MEDS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MEDS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MEDS
DataMeds AI, Inc. (MEDS) is a specialty pharmaceutical company focused on improving medication adherence and reducing healthcare costs through a business model that targets the high-cost specialty drug market, where it aims to offer competitive cash formularies and wholesale operations.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
DataMeds AI, Inc. (MEDS) is a specialty pharmaceutical company focused on improving medication adherence and reducing healthcare costs through a business model that targets the high-cost specialty drug market, where it aims to offer competitive cash formularies and wholesale operations.
- The specialty drug market accounts for less than 10% of total drugs but is responsible for greater than 50% of prescription drug spend per annum [sec · filed 2026-08-07].
- The company believes poor medication adherence is a key driver of healthcare costs, and its model aims to address this by empowering patient autonomy and providing clinical support [sec · filed 2026-08-07].
- DataMeds plans to expand wholesale operations by partnering with manufacturers to offer products not typically carried by the three largest U.S. wholesalers, seeking exclusivity or semi-exclusive arrangements [sec_mda · as of 2026-08-17].
- As of June 30, 2026, the company reported cash & equivalents of $2.5M, total revenue of $1.8M, net income of -$18.4M, shareholders' equity of -$12.4M, and total debt of $43.9M [sec].
- The company has a going concern uncertainty and is actively seeking additional financing through equity, debt, or strategic partnerships [sec_mda · as of 2026-08-17].
What works
- DataMeds targets the high-value specialty drug market, which represents a significant portion of prescription drug spending, offering a large addressable market [sec · filed 2026-08-07].
- The company's strategy to offer competitive cash formularies and wholesale products not carried by major wholesalers could differentiate it in the market [sec_mda · as of 2026-08-17].
- Management is actively pursuing multiple financing avenues, including equity, debt, and strategic partnerships, to support ongoing operations [sec_mda · as of 2026-08-17].
What to weigh
- The company has a substantial net loss of $18.4M for the quarter ended June 30, 2026, and an accumulated deficit reflected in negative shareholders' equity of -$12.4M [sec].
- DataMeds has a going concern uncertainty, with its ability to continue as a going concern dependent on obtaining additional financing [sec_mda · as of 2026-08-17].
- The company carries a high debt load of $43.9M relative to its cash position of $2.5M, indicating significant financial leverage [sec].
- The company's forward-looking statements highlight risks including the ability to generate revenue or achieve profitability and obtain financing on acceptable terms [sec · filed 2026-08-07].
From the filings
Quoted directly from source documents.
Specialty drugs represent a small fraction of total drugs but a majority of prescription drug spend.
“the specialty drug market accounts for less than 10% of total drugs in the market but is responsible for greater than 50% of the prescription drug spend per annum.”
SEC filings · August 7, 2026
The company's net loss for the three months ended June 30, 2026 was $18.4 million.
“three months ended June 30, 2026 was $18,363,225”
SEC MD&A · August 17, 2026
The company has a going concern uncertainty and is seeking additional financing.
“The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.”
SEC MD&A · August 17, 2026
DataMeds plans to wholesale products not carried by the three largest U.S. wholesalers.
“We have strategically identified opportunities to wholesale products that are normally not carried by the three largest wholesalers in the United States”
SEC filings · August 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company's financial statements are prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to do so without additional financing [sec_mda · as of 2026-08-17].
- High debt and negative equity — As of June 30, 2026, total debt is $43.9M against cash of $2.5M and negative shareholders' equity of -$12.4M, indicating a highly leveraged capital structure [sec].
- Dependence on external financing — The company's ability to fund operations depends on obtaining additional capital through equity, debt, or partnerships, with no assurance of availability on acceptable terms [sec_mda · as of 2026-08-17].
- History of net losses — The company reported a net loss of $18.4M for the quarter ended June 30, 2026, and $26.1M for the six-month period, reflecting ongoing unprofitability [sec_mda · as of 2026-08-17].
What to watch
- Ability to secure additional financing (equity, debt, or partnerships) to address going concern and fund operations [sec_mda · as of 2026-08-17].
- Progress in establishing manufacturer partnerships and wholesale exclusivity agreements for specialty products [sec_mda · as of 2026-08-17].
- Trends in revenue growth and net loss reduction, particularly as the company scales its wholesale operations [sec_mda · as of 2026-08-17].
- Any updates on the company's cash position and debt management, given the high leverage and negative equity [sec].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run DataMeds AI, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DataMeds AI, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.5 months
OCF -$3M · Net income -$18M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$257K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,208,452 | $116K |
| geode capital management, llc | 710,766 | $69K |
| vanguard fiduciary trust co | 309,584 | $30K |
| state street corp | 124,600 | $12K |
| jane street group, llc | 93,980 | $9K |
| northern trust corp | 74,063 | $7K |
| raymond james financial inc | 58,421 | $6K |
| xtx topco ltd | 31,501 | $3K |
| valley forge investment consultants inc adv | 22,988 | $2K |
| aqr capital management llc | 20,293 | $2K |
Showing top 10 of 11 institutional holders of DataMeds AI, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 0.1
- Shares short
- 2,676,448
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MEDS short interestFrequently asked questions
What is the AI investment thesis for DataMeds AI, Inc.?
DataMeds AI, Inc. (MEDS) is a specialty pharmaceutical company focused on improving medication adherence and reducing healthcare costs through a business model that targets the high-cost specialty drug market, where it aims to offer competitive cash formularies and wholesale operations.
Who is the CEO of DataMeds AI, Inc.?
Mr. Prashant Patel M.Sc., R.Ph. is the chief executive officer of DataMeds AI, Inc. (MEDS).
Where is DataMeds AI, Inc. headquartered?
DataMeds AI, Inc. (MEDS) is headquartered in Tampa, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.